
A study analyzed deaths from COVID-19 in Korea and found male patients in 70s with chronic cardiac disorder like hypertension were critically affected.
Apparently, most of them had died in average 10 days after the onset COVID-19 symptoms, and their average time to death was unaffected regardless of underlying illness.
First epidemiological report by Korean Society of Infectious Diseases on death due to COVID-19 in Korea Korean Society of Infectious Diseases (KSID) has investigated 53 deaths, as of Mar.
15, from 7,513 patients infected by coronavirus in Korea and published the outcome on the Journal of Korean Medical Science on Mar.
30 (doi.org/10.3346/jkms.2020.35.e132).

The investigation found, as of Mar.
15, total 5,833 cases resulted in death among 156,400 confirmed cases of COVID-19 around the world, which recorded 3.7 percent mortality rate.
In Korea, the rate was at 0.7 percent with 54 deaths.
On Feb.
19, the 104th confirmed case of COVID-19 in Korea has been deceased and was reported as the first COVID-19 caused death in Korea on the next day.
And the 443rd case was the first death reported to have been confirmed positive posthumously on Feb.
21.
Other than the two, the investigators highlighted the 1,443rd case reported on Feb.
27, as the patient was the first death reported during their self-isolation period.
On Mar.
3, the 32nd case has reportedly been deceased without an underlying illness.
The investigators also emphasized the descending trend of mortality rate while the number of confirmed cases has exponentially surged since the first death reported.
They pointed out it indicates the management over patient with high severity is taking its place.
In fact, on Feb.
20 when the first death was reported, the case fatality rate (CFR) was at 1.22 percent.
But the CFR was dropped to 0.04 percent, as of Mar.
10.

Mar.
30, the COVID-19 CFR in Korea was at 0.7 percent.
Categorized by each region, the number of deaths was highest in Daegu and Northern Gyeongsang Province, where 85 percent of confirmed cases were concentrated in.
Daegu along had 38 patients died from COVID-19, but 13 have lost their lives in Northern Gyeongsang Province.
However, the researchers pointed out the statistic figures are not an absolute indicator as a patient from Gangwon Province has died in a Northern Gyeongsang Province hospital, and patients from the Northern Gyeongsang Province have been treated at National Medical Center.
Male patients in 70s with underlying health condition, three key words in COVID-19 death So who is most vulnerable to COVID-19?
First, the investigators set down three key words—70s, male and underlying cardiovascular disorder.
Analyzing critical cases resulted in deaths, the investigation found the median age at death was 75.5.
And the mortality rate was higher in male patients at 61.1 percent than in female patients.
The most prevalent underlying health condition was cardiovascular disease.
The CFR analysis in the report supports the findings clearly.
The CFR in male patients was at 1.16 percent with 33 deaths among 2,852 cases, but the rate was at 0.45 percent in female patients with only 21 deaths within 4,661 cases.
The gap between sexes was even more significant in the older age group.
The mortality rate in male patients 60 and over was at 4.73 percent with eight deaths in 592 cases, where as the rate in female patients in the same age group was at 1.88 percent with 19 deaths in 1,013 cases.

The CFR in age group of under 20 and 20s to 50s were at zero percent and 0.05 percent, respectively.
But from the age group of 50 and up, the CFR was increased to 1.72 percent.
Most of the deaths were reported with underlying health condition.
Within 90.7 percent of deaths with underlying illnesses, 59.3 percent of them had cardiac disorder like hypertension, making it the most prevalent underlying disorder followed by diabetes and neurologic disease like dementia.
The median time from onset symptoms to death of the particular patient group was ten days, regardless of their sex.
And also the underlying illness has not affected the duration of survival time.
The investigators explained, “Mortality rate is the most crucial indicator to consider when setting the prioritization of infectious disease control.
Although it is too early to compare the tendencies with different countries, mortality rate ascending after identifying a mass infection was a meaningful finding.” “The most vital strategy is to maintain the capability of hospitals treating patients in initial stage to severe state by carefully and appropriately reviewing the disease,” and “As these key words from the investigation are the most significant key words as the mortality rate around the world is surging, an improved response with broader perspective based on them is needed.,” the investigators added.
댓글 운영방식은
댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.
댓글 노출방식은
댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.
댓글의 삭제 기준은
다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.
저작권·인격권 등 타인의 권리를 침해하는 경우
상용 프로그램의 등록과 게재, 배포를 안내하는 게시물
타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물
근거 없는 비방·명예를 훼손하는 게시물
특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우
특정 지역 및 종교간의 감정대립을 조장하는 내용
사실 확인이 안된 소문을 유포 시키는 경우
욕설과 비어, 속어를 담은 내용
정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)
특정 지역이나 단체를 비하하는 경우
특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우
특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우
타인의 ID 혹은 닉네임을 도용하는 경우
게시판 특성상 제한되는 내용
서비스 주제와 맞지 않는 내용의 글을 게재한 경우
동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우
부분적으로 변경하여 반복 게재하는 경우도 포함
제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우
돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물
게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우
수사기관 등의 공식적인 요청이 있는 경우
기타사항
각 서비스의 필요성에 따라 미리 공지한 경우
기타 법률에 저촉되는 정보 게재를 목적으로 할 경우
기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용
사실 관계 확인 후 삭제
저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우
타인의 초상권을 침해하거나 개인정보를 유출하는 경우
당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)
※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.
※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.
※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.